Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will World's Largest HCV Population Have Access To Newest Treatments?

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck will work with the Chinese Physician Association on an HCV awareness campaign.

You may also be interested in...



Merck/Roche Co-Promote Pact Attempts To Shut Vertex Out Of HCV Protease Inhibitor Space

Roche will co-promote Merck's Victrelis with its own HCV drugs Pegasys and Copegus in the U.S.

Merck Looks To Leverage "Next 10" For Growth: Emerging Markets Earnings Roundup (Part 4)

Emerging markets remained a key focus of Big Pharma during first quarter earnings calls. Merck & Co., which aims to see one-fourth of its revenue come from emerging markets by 2013, focused investment in best growth drivers and sales efficiency to bolster key products. Merck's emerging markets strategy will focus on maximizing its own brands, leveraging partnerships with low-cost makers and looking for "inter-brand" opportunities.

Mitsubishi Tanabe's Key Products And M&A Rumors Tempered By Management Issues

TOKYO - Mitsubishi Tanabe has industry observers scratching their heads. On one hand, the company has rights in Asia for telaprevir, a high-profile hepatitis C treatment, and its oral multiple sclerosis therapy Gilenya (fingolimod) recently gained approval in the U.S. through ex-Japan licensee Novartis and is on file for approval in Japan. But the company's repeated supply chain irregularities raise concern over management's ability to handle its manufacturing quality control process

Related Content

Topics

UsernamePublicRestriction

Register

PS072273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel